NewEdge Advisors LLC Sells 27,583 Shares of Boston Scientific Corporation $BSX

NewEdge Advisors LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 29.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 65,461 shares of the medical equipment provider’s stock after selling 27,583 shares during the period. NewEdge Advisors LLC’s holdings in Boston Scientific were worth $4,108,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Optiver Holding B.V. bought a new position in Boston Scientific in the first quarter valued at about $852,000. Caerus Investment Advisors LLC bought a new stake in Boston Scientific during the 1st quarter worth about $236,000. First Nebraska Trust Co bought a new stake in Boston Scientific during the 1st quarter worth about $6,594,000. Keel Point LLC lifted its position in Boston Scientific by 8.0% during the 1st quarter. Keel Point LLC now owns 41,464 shares of the medical equipment provider’s stock valued at $2,602,000 after purchasing an additional 3,064 shares during the period. Finally, Blue Fin Capital Inc. boosted its stake in shares of Boston Scientific by 12.9% in the 1st quarter. Blue Fin Capital Inc. now owns 14,795 shares of the medical equipment provider’s stock valued at $928,000 after purchasing an additional 1,696 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BSX shares. TD Cowen dropped their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Citigroup lowered their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Oppenheimer cut their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director directly owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 0.4%

Boston Scientific stock opened at $51.40 on Thursday. The firm has a market capitalization of $74.49 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56. The company’s 50 day simple moving average is $45.94 and its 200 day simple moving average is $59.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.